To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

A Single-center Safety and Tolerability Study to Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder

The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.

Inclusion Criteria:

• Diagnosis of Schizophrenia or Schizoaffective disorder
• 18-55 years

Exclusion Criteria:

• Subjects who are acutely psychotic
• Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia
• Subjects at significant risk of suicide
• Subjects with a seizure disorder